ERBB2 amplification was detected in the CGH study for SEC1, SEC2 (both the primary tumor and metastasis) and SEC3 (only in metastasis), while the IHC analysis of different tumor regions reflects the ITGH in the patient and could reveal new targets for available treatments. Here, ERBB2 is linked to neoplasm.